A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
- Registration Number
- NCT02414516
- Lead Sponsor
- Oncolys BioPharma Inc
- Brief Summary
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description OBP-801 OBP-801 -
- Primary Outcome Measures
Name Time Method Maximum Tolerated Dose 6 weeks
- Secondary Outcome Measures
Name Time Method Durability of Objective Response (DOR) 22 weeks Objective Response (OR) 22 weeks Pharmacokinetic (PK) profile; AUC, Cmax, and t1/2 4 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does OBP-801 utilize to target advanced solid tumors in phase 1 trials?
How does OBP-801 compare to standard-of-care treatments for advanced solid tumors in terms of efficacy and safety?
What biomarkers are associated with patient response to OBP-801 in Oncolys BioPharma's phase 1a study?
What are the potential adverse events and management strategies for OBP-801 in cancer patients?
Are there combination therapies or competitor drugs to OBP-801 for treating advanced solid tumors?
Trial Locations
- Locations (1)
Barbara Ann Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Barbara Ann Karmanos Cancer Institute🇺🇸Detroit, Michigan, United States